



Republic of the Philippines
Department of Health
FOOD AND DRUG ADMINISTRATION



FDA ADVISORY

No. **2020-1271**

JUN 24 2020

TO : ALL HEALTHCARE PROFESSIONALS AND THE GENERAL PUBLIC

SUBJECT : Public Health Warning Against the Purchase and Use of the Following Unregistered Drug Products:

1. Sanglianpai® Sai wei'an Jiaonang
2. Clindamycin Phosphate Injection 2ml : 0.3g [as reflected in the secondary packaging]
3. Vitamin B6 Injection 2ml : 0.1g
4. Viaminate Capsules
5. OTC Bausch + Lomb
6. Compound Miconazole Nitrate Cream
7. OTC Cyproheptadine Hydrochloride Cream
8. Triamcinolone Acetonide Nasal Spray
9. OTC Fufang Zaoren Jiaonang [as reflected in the package insert]
10. Dexamethasone Acetate Cream 10g
11. OTC Clotrimazole Cream [as reflected in the secondary packaging]
OTC Kemeizuo Rugao [as reflected in the primary packaging]
12. OTC Compound Paracetamol and Amantadine Hydrochloride Tablets
13. OTC Paracetamol, Caffeine, Artificial Cow-bezoar and Chlorphenamine Maleate Capsules [as reflected in the package insert]
14. Dexamethasone Acetate Oral Mucoadhesive Patches [as reflected in the package insert]
15. OTC Shibiao Yaoye
16. OTC Qing Yuan Calcium Gluconate Tablets
17. OTC [Label in Foreign Language]
18. Sine® Pipemidic Acid Tablets 0.25g
19. SPH H31020387 [Label in Foreign Language] 0.4g x 80mg
20. OTC Multienzyme Tablets
21. H21022500 [Label in Foreign Language] 25mg
22. Phenolphthalein Tablets 100mg
23. Hydrochlorothiazide Tablets
24. Dexamethasone Acetate Tablets 0.75mg
25. Nimodipine Tablets 20mg
26. Griseofulvin Tablets 0.1g
27. OTC Sanhuangpian
28. H33022029 [Label in Foreign Language]
29. H51023736 [Label in Foreign Language] 50mg



The Food and Drug Administration (FDA) advises the public against the purchase and use of the following unregistered drug products:



Figure 1. Unregistered drug product




Figure 2. Unregistered drug product



Figure 3. Unregistered drug product



Figure 4. Unregistered drug product



Figure 5. Unregistered drug product



Figure 6. Unregistered drug product



Figure 7. Unregistered drug product



Figure 8. Unregistered drug product



Figure 9. Unregistered drug product



Figure 10. Unregistered drug product



Figure 11. Unregistered drug product




Figure 12. Unregistered drug product




Figure 13. Unregistered drug product



Figure 14. Unregistered drug product



OTC SHIBIAO YAOZE

Figure 15. Unregistered drug product



OTC QING YUAN Calcium Gluconate Tablets

Figure 16. Unregistered drug product



Figure 17. Unregistered drug product



Figure 18. Unregistered drug product



Figure 19. Unregistered drug product



Figure 20. Unregistered drug product



H21022500 [Label in Foreign Language] 25mg

Figure 21. Unregistered drug product



Phenolphthalein Tablets 100mg

Figure 22. Unregistered drug product



Figure 23. Unregistered drug product



Figure 24. Unregistered drug product



Figure 25. Unregistered drug product



Figure 26. Unregistered drug product



Figure 27. Unregistered drug product



Figure 28. Unregistered drug product



Figure 29. Unregistered drug product

FDA Post-Marketing Surveillance (PMS) activities have verified that the abovementioned drug products have not gone through the registration process of the Agency and have not been issued with proper authorization in the form of Certificate of Product Registration. Thus, the Agency cannot guarantee its quality, safety and efficacy. Therefore, consumption of such violative products may pose potential danger or injury to health.


Pursuant to Republic Act No. 9711, otherwise known as the “Food and Drug Administration Act of 2009”, the manufacture, importation, exportation, sale, offering for sale, distribution, transfer, promotion, advertising or sponsorship of health products without proper authorization from FDA is prohibited.

All concerned establishments and/or entities are warned not to distribute the above-identified violative drug products until they have already been covered by the appropriate authorization, otherwise, regulatory actions and sanctions shall be strictly pursued.

All Local Government Units (LGUs) and Law Enforcement Agencies (LEAs) are requested to ensure that these products are not sold or made available in their localities or areas of jurisdiction.

For more information and inquiries, please e-mail us at info@fda.gov.ph. To report continuous sale or distribution of unregistered health products, kindly e-mail us via ereport@fda.gov.ph. You may also call the Center for Drug Regulation and Research at telephone number (02) 8809-5596. For any suspected adverse drug reaction (ADR), report immediately to FDA through this link: <https://primaryreporting.whoumc.org/Reporting/Reporter?OrganizationID=PH> and fill out all the required fields.

Dissemination of the information to all concerned is requested.


ROLANDO ENRIQUE D. DOMINGO, MD
Director General

DTN: 
20200528085802